StreetInsider.com News Articles

AI/ML Innovations Announces Completion of Share Issuance

Thu, 02 Jul 2026 17:05:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO, ON / ACCESS Newswire / July 2, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 3,560,334 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share in consideration of past services and satisfaction of outstanding indebtedness (the

AI/ML Innovations Announces Completion of Share Issuance

Thu, 02 Jul 2026 17:05:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

AI/ML Innovations Inc. Announces Grant of U.S. Patent Expanding Protection for AI-Driven ECG Analysis

Tue, 23 Jun 2026 07:00:00 -0400

Patent covers machine learning techniques for ECG denoising, rhythm classification, sample-level labelling, wearable cardiac monitoring, and report generation

TORONTO, ON / ACCESS Newswire / June 23, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leader in AI-powered physiological signal interpretation, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has been granted U.S. Patent No. 12,622,625 B2, titled "Machine Learning Techniques for Electrocardiogram (ECG) Analysis."

The patent, issued by the United States Patent and Trademark Office, expands NeuralCloud's intellectual property protection around the Company's proprietary AI-based

AI/ML Innovations Inc. Announces Grant of U.S. Patent Expanding Protection for AI-Driven ECG Analysis

Tue, 23 Jun 2026 07:00:00 -0400

Patent covers machine learning techniques for ECG denoising, rhythm classification, sample-level labelling, wearable cardiac monitoring, and report generation

The patent, issued by the United States Patent and Trademark Office, expands NeuralCloud's intellectual property protection around the Company's proprietary AI-based

AI/ML Subsidiary NeuralCloud Appoints Cardiac Monitoring Veterans Dale and Nicholas DuBois to Lead Clinical and Overread Operations

Tue, 02 Jun 2026 07:00:00 -0400

Appointments bring more than 50 combined years of cardiac monitoring, ECG overread (the expert clinical review of ECG recordings by trained technicians and cardiologists), and regulatory validation experience to NeuralCloud's clinical and operational leadership team.
Leadership additions strengthen AI/ML's clinical-governance and operational readiness as it advances its neural-network ECG signal-processing technology through regulatory review toward potential future commercialization.

TORONTO, ON / ACCESS Newswire / June 2, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company"), (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that its wholly-owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has appointed Dale DuBois, ASN,

AI/ML Subsidiary NeuralCloud Appoints Cardiac Monitoring Veterans Dale and Nicholas DuBois to Lead Clinical and Overread Operations

Tue, 02 Jun 2026 07:00:00 -0400

Appointments bring more than 50 combined years of cardiac monitoring, ECG overread (the expert clinical review of ECG recordings by trained technicians and cardiologists), and regulatory validation experience to NeuralCloud's clinical and operational leadership team.
Leadership additions strengthen AI/ML's clinical-governance and operational readiness as it advances its neural-network ECG signal-processing technology through regulatory review toward potential future commercialization.

AI/ML Innovations closes final tranche of private placement for $1.92M

Mon, 11 May 2026 22:21:13 -0400

AI/ML Innovations Inc. (CSE: AIML) completed the second and final tranche of its non-brokered private placement, raising $1,917,500 through convertible debentures. Combined with the first tranche, the company has issued debentures totaling $2,867,500.

The debentures can be converted into units at $0.05 per unit at the holder's option. Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.15 each for 36 months from issuance.

The debentures carry a 10% annual interest rate and mature on May 11, 2029. Accrued interest can also be converted into units under the same terms. Securities

AI/ML Innovations Inc. Announces Closing of Final Tranche of Private Placement to Raise $1,917,500

Mon, 11 May 2026 22:20:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO, ON / ACCESS Newswire / May 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued convertible debentures ("Debentures") in the aggregate principal amount of $1,917,500. Together with the first tranche closing, the Company has issued Debentures in the aggregate principal amount of $2,867,500.

The Debentures

AI/ML Innovations Inc. Announces Closing of Final Tranche of Private Placement to Raise $1,917,500

Mon, 11 May 2026 22:20:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

The Debentures

AIML appoints cardiac electrophysiology expert to medical advisory board

Mon, 11 May 2026 07:02:45 -0400

AI/ML Innovations Inc. (CSE:AIML) announced the appointment of Dr. Martin Green to its Medical Advisory Board, effective April 27, 2026. The company also granted 4 million stock options to employees at $0.10 per share, exercisable for five years.

Dr. Green is Professor Emeritus at the University of Ottawa and recently retired as Cardiologist and Cardiac Electrophysiologist at the University of Ottawa Heart Institute. He established the institute's Arrhythmia Service in 1983 and served as Director of the EP Fellowship Program from 1983-2017.

The appointment was made at the invitation of Dr. Paul Dorian, AIML's Medical Innovation Architect and Chair of the Medical

AIML Appoints Dr. Martin Green to Medical Advisory Board and Issue Options

Mon, 11 May 2026 07:00:00 -0400

Founding Architect of Canadian Cardiac Electrophysiology and 45-Year Authority on Electrocardiography Joins AIML's Medical Advisory Board

TORONTO, ON / ACCESS Newswire / May 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Martin Stephen Green, MD, FRCPC, Professor Emeritus at the University of Ottawa, to the Company's Medical Advisory Board (the "MAB"), effective April 27, 2026.

Dr. Green joins the MAB at the invitation of Dr. Paul Dorian, MD, MSc., the Company's Medical Innovation Architect and Chair of the Medical Advisory Board. The

AIML Appoints Dr. Martin Green to Medical Advisory Board and Issue Options

Mon, 11 May 2026 07:00:00 -0400

Founding Architect of Canadian Cardiac Electrophysiology and 45-Year Authority on Electrocardiography Joins AIML's Medical Advisory Board

Dr. Green joins the MAB at the invitation of Dr. Paul Dorian, MD, MSc., the Company's Medical Innovation Architect and Chair of the Medical Advisory Board. The

AI/ML Innovations Announces Completion of Share Issuance

Fri, 24 Apr 2026 19:51:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO, ON / ACCESS Newswire / April 24, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share totalling Cdn$855,921 in consideration of past services and satisfaction of outstanding

AI/ML Innovations Announces Completion of Share Issuance

Fri, 24 Apr 2026 19:51:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

AI/ML Innovations Announces Completion of Share Issuance

Fri, 17 Apr 2026 20:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO, ON / ACCESS Newswire / April 17, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share in consideration of past services and satisfaction of outstanding indebtedness.

The Subject

AI/ML Innovations Announces Completion of Share Issuance

Fri, 17 Apr 2026 20:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

The Subject

Neural Cloud signs reseller deal with European cardiac monitoring platform

Tue, 31 Mar 2026 07:00:12 -0400

AI/ML Innovations Inc. (CSE: AIML) announced that its subsidiary Neural Cloud Solutions Inc. entered into a reseller agreement on March 25, 2026 with a European digital health platform specializing in cloud-based ECG and heart rate variability analytics.

Under the agreement, the European partner will integrate and resell Neural Cloud's MaxYield ECG signal-processing technology to its customers as either a standalone capability or as part of a bundled remote cardiac monitoring solution.

The partner platform delivers remote heart health monitoring, enabling clinicians to track cardiovascular signals through connected devices and cloud-based analytics. The system provides cardiac health reports and detection of cardiac abnormalities

Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform

Tue, 31 Mar 2026 07:00:00 -0400

Collaboration Expands Reach of MaxYield^™ into Remote Heart Monitoring and Preventive Cardiology Applications

TORONTO, ON / ACCESS Newswire / March 31, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) today announced that its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), entered into a reseller agreement on March 25^th, 2026 with a European-based digital health platform specializing in cloud-based ECG and heart rate variability (HRV) analytics.

Under the agreement, the partner platform will integrate and resell Neural Cloud's MaxYield^™ ECG signal-processing technology to its customers as either a standalone capability or

Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform

Tue, 31 Mar 2026 07:00:00 -0400

Collaboration Expands Reach of MaxYield^™ into Remote Heart Monitoring and Preventive Cardiology Applications

Under the agreement, the partner platform will integrate and resell Neural Cloud's MaxYield^™ ECG signal-processing technology to its customers as either a standalone capability or

AIML closes first tranche of private placement raising $950,000

Fri, 27 Mar 2026 17:00:10 -0400

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) closed the first tranche of its non-brokered private placement, issuing convertible debentures totaling $950,000 in principal amount.

The debentures can be converted into company units at $0.05 per unit at the holder's discretion. Each unit consists of one common share and one warrant exercisable at $0.15 per share for 36 months from issuance. The debentures carry a 10% annual interest rate and mature on March 27, 2029.

Company insiders purchased $550,000 of the debentures, making this a related party transaction under Multilateral Instrument 61-101. The company qualified for exemptions from formal valuation and minority shareholder approval requirements because

AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000

Fri, 27 Mar 2026 17:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO, ON / ACCESS Newswire / March 27, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued convertible debentures ("Debentures") in the aggregate principal amount of $950,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any

AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000

Fri, 27 Mar 2026 17:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis

Wed, 25 Mar 2026 07:00:00 -0400

Agreement expands NeuralCloud's role in cardiovascular research and academic collaborations
MaxYield^™ platform to support heart rate variability analysis in post-exertional malaise research

TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that on March 18^th, 2026 the Company entered into a research services agreement with Dr. Kegan Moneghetti, MBBS (Hons) FRACP FCSANZ PhD, of the Baker Heart and Diabetes Institute, to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study.

Under

AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis

Wed, 25 Mar 2026 07:00:00 -0400

Agreement expands NeuralCloud's role in cardiovascular research and academic collaborations
MaxYield^™ platform to support heart rate variability analysis in post-exertional malaise research

Under

AI/ML Innovations proposes $3 million convertible debenture offering

Thu, 12 Mar 2026 19:31:10 -0400

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) announced a proposed non-brokered private placement to issue convertible debentures with a principal amount of up to $3 million.

The debentures may be converted into company units at the holder's option at a conversion price of $0.05 per unit. Each unit comprises one common share and one warrant. The warrants are exercisable at $0.15 per share for 36 months from issuance.

The debentures will bear 10% annual interest, payable upon maturity or conversion. Accrued unpaid interest may also be converted into units under the same terms. The debentures mature three years from the issuance date.

The offering requires various